Remove Heart attacks Remove Heart Disease Remove Heart Failure
article thumbnail

Experimental drug engineered to prevent heart failure after heart attacks

Science Daily - Heart Disease

An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance tissue repair in the heart following a heart attack.

article thumbnail

Is long-term beta-blocker therapy needed after a heart attack?

Science Daily - Heart Disease

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason.

article thumbnail

Immunotherapy blocks scarring, improves heart function in mice with heart failure

Science Daily - Heart Disease

Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other conditions.

article thumbnail

Born to heal: Why babies recover, but adults scar, after heart damage

Science Daily - Heart Disease

Newborns with heart complications can rely on their newly developed immune systems to regenerate cardiac tissues, but adults aren't so lucky. After a heart attack, most adults struggle to regenerate healthy heart tissue, leading to scar-tissue buildup and, often, heart failure.

article thumbnail

Proposed risk factor tool finds heart failure rates are higher among American Indian adults

Science Daily - Heart Disease

An analysis based on a proposed heart failure risk prediction tool reveals that the incidence of heart failure may be 2- to 3-fold higher among American Indian adults compared to people in other population groups.

article thumbnail

Study reveals target for reversing scar tissue after heart attack

Science Daily - Heart Disease

New research discovers a potential path to prevent permanent scarring and heart failure following a myocardial infarction.

article thumbnail

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

Science Daily - Heart Disease

New research shows sotagliflozin is the only drug in its class to demonstrate these results.